ZDA
DNLI icon

Zweig-DiMenna Associates’s Denali Therapeutics DNLI Stock Holding History

Zweig-DiMenna Associates’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30,100
Closed -$1.08M – 146
2020
Q3 		$1.08M Buy
+30,100
New +$907K 0.07% 123

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zweig-DiMenna Associates's DNLI Position: Q4 2020 in Review

Zweig-DiMenna Associates sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 30,100 shares — an estimated $1.08M sold.

Zweig-DiMenna Associates first reported a position in DNLI in Q3 2020 and held it in 1 quarter. The position peaked at $1.08M in Q3 2020. 204 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Zweig-DiMenna Associates reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 30,100 Denali Therapeutics shares in Q4 2020, an estimated $1.08M.
  • Zweig-DiMenna Associates first reported a position in Denali Therapeutics in Q3 2020 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Denali Therapeutics position peaked at $1.08M in Q3 2020.
  • 204 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2020, filed 26 Jan 2021.